Home › Atrial Fibrillation › NCT07651852

Globe Registry: Globe® Pulsed Field System Registry Study for Treating Patients With Symptomatic Atrial Fibrillation

Who can join

Ages 18 and older · All sexes

Key Inclusion Criteria:

* Patients with a planned ablation procedure using the commercially available Globe PF System

Key Exclusion Criteria:

* Patients whose life expectancy is 1 year or less
* Contraindication to left atrial catheter ablation or PF ablation
* Current enrollment in any investigational study of a medical device, biologic, or drug not pre-approved by Kardium

About the study

This post-market registry is designed to collect real world data on the use of the Globe PF System for the treatment of atrial fibrillation (AF).

What is being tested

• Globe Pulsed Field System (device)

Sponsor: Kardium Inc. · Participants: 500 · Started: Oct 9, 2026

Contact the study team

• Clinical Affairs · Phone: +1 (604) 248 8891

Official record on ClinicalTrials.gov — NCT07651852

Locations in the U.S.

Conditions

• Atrial Fibrillation

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.